Find articles by Baggio, L
Common DPP-4 Inhibitors: Key Features of DPP-4 Inhibitors: Enhancing GLP-1 Activity: Prevents the rapid degradation of GLP-1, thereby sustaining its glucose-lowering effects
Our integrated approach has led to more than 96% of Oshi patients on GLP-1s reporting improvement and control over their symptoms within six months of starting care, which led to better reported quality of life and increased medication adherence
In this study, 480 PsA patients were randomized to golimumab 2 mg/kg, administered at 0, 2, 4, 12 and 20 weeks, or placebo
The clinical trial, LIBERATE-1, will evaluate the safety, tolerance, and pharmacological effects of the GLP-1 implant in overweight and obese individuals
Storage effect: The adjuvant stores the antigen during the vaccine immune response and slowly releases it to achieve a sustained and long-lasting stimulation of the body's immune system